Summit Therapeutics

Summit Therapeutics Current Ratio

The Current Ratio of Summit Therapeutics (SMMT) as of Nov 22, 2026 is 10.14. In the previous year, Current Ratio was 9.30 — a change of 9.08% (higher).

Current Ratio

10.14

YoY

9.08%

Last updated:

Current Ratio of Summit Therapeutics is 2024 10.14 . Current Ratio of Summit Therapeutics was 2023 9.30 . It decreases by 9.08% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Summit Therapeutics Stock analysis

What does Summit Therapeutics do? Summit Therapeutics Inc. is a global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines for the treatment of life-threatening and rare diseases. The company is headquartered in Massachusetts, USA and also has offices in Oxford, UK. Summit Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Summit Therapeutics stock

Current Ratio of Summit Therapeutics is 10.14 in 2024.

Current Ratio of Summit Therapeutics changed from 9.30 to 10.14, representing a 9.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio Summit Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's Summit Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Summit Therapeutics

All Key Metrics — Summit Therapeutics